Alivus Life Sciences Limited

NSEI:GLS Stock Report

Market Cap: ₹124.6b

Alivus Life Sciences Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Yasir Rawjee

Chief executive officer

₹272.4m

Total compensation

CEO salary percentage99.2%
CEO tenure5.6yrs
CEO ownershipn/a
Management average tenure2.9yrs
Board average tenure1.5yrs

Recent management updates

Recent updates

Glenmark Life Sciences Limited Recorded A 7.3% Miss On Revenue: Analysts Are Revisiting Their Models

Aug 07
Glenmark Life Sciences Limited Recorded A 7.3% Miss On Revenue: Analysts Are Revisiting Their Models

A Look At The Fair Value Of Glenmark Life Sciences Limited (NSE:GLS)

May 10
A Look At The Fair Value Of Glenmark Life Sciences Limited (NSE:GLS)

Why Investors Shouldn't Be Surprised By Glenmark Life Sciences Limited's (NSE:GLS) Low P/E

Feb 15
Why Investors Shouldn't Be Surprised By Glenmark Life Sciences Limited's (NSE:GLS) Low P/E

CEO Compensation Analysis

How has Yasir Rawjee's remuneration changed compared to Alivus Life Sciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

₹4b

Jun 30 2024n/an/a

₹4b

Mar 31 2024₹272m₹270m

₹5b

Dec 31 2023n/an/a

₹5b

Sep 30 2023n/an/a

₹5b

Jun 30 2023n/an/a

₹5b

Mar 31 2023₹55m₹53m

₹5b

Dec 31 2022n/an/a

₹4b

Sep 30 2022n/an/a

₹4b

Jun 30 2022n/an/a

₹4b

Mar 31 2022₹66m₹65m

₹4b

Dec 31 2021n/an/a

₹4b

Sep 30 2021n/an/a

₹4b

Jun 30 2021n/an/a

₹4b

Mar 31 2021₹51mn/a

₹4b

Mar 31 2020₹29m₹28m

₹3b

Compensation vs Market: Yasir's total compensation ($USD3.20M) is above average for companies of similar size in the Indian market ($USD474.49K).

Compensation vs Earnings: Yasir's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.

CEO

Yasir Rawjee (59 yo)

5.6yrs

Tenure

₹272,350,000

Compensation

Dr. Yasir Yusufali Rawjee, Ph D., serves as Managing Director, Director and Chief Executive Officer of Glenmark Life Sciences Limited since August 13, 2019. Dr. Rawjee served as Senior Vice President of My...

Leadership Team

NamePositionTenureCompensationOwnership
Yasir Rawjee
CEO, MD & Director5.6yrs₹272.35mno data
Tushar Mistry
Senior VP & CFO2.5yrs₹51.07mno data
Vinod Naik
Group VPno data₹56.56mno data
Rudalf Corriea
Company Secretary & Compliance Officer3.8yrs₹2.35mno data
Soumi Rao
General Manager of Corporate Communicationsno datano datano data
Sumantra Mitra
Senior VP & Head of Human Resourcesno data₹18.20mno data
Mathew George
Senior VP & Head of Regulatory Affairs2.9yrsno datano data
Navin Agrawal
VP & Head of Corporate Quality2.9yrsno datano data

2.9yrs

Average Tenure

Experienced Management: GLS's management team is considered experienced (2.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Yasir Rawjee
CEO, MD & Director5.3yrs₹272.35mno data
Vinod Naik
Group VP2.2yrs₹56.56mno data
Kaushikbhai Patel
Additional Independent Directorless than a year₹200.00kno data
Hirenbhai Patel
Non Executive Chairmanless than a yearno datano data
Taruvai Easwar
Non-Executive Independent Director3.9yrs₹1.60mno data
Manju Agarwal
Non-Executive Independent Director4.2yrs₹1.70m0.00082%
₹ 1.0m
Vijaykumar Shah
Additional Independent Directorless than a year₹200.00kno data
Savan Godiawala
Additional Independent Directorless than a yearno datano data

1.5yrs

Average Tenure

63yo

Average Age

Experienced Board: GLS's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 17:52
End of Day Share Price 2024/12/19 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Alivus Life Sciences Limited is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Saad ShaikhBOB Capital Markets Ltd.
Neha ManpuriaBofA Global Research
Nitin AgarwalDAM Capital Advisors